Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen CoFRA:REG +13.97%46 12-1 Month Momentum % is 39.44% as of Aug. 07, 2026. GuruFocus rates FRA:REG with a GF Score™ of 46/100 and a GF Value™ of €19.59 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,359 Biotechnology companies, RemeGen Co ranks better than 76.23% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-07), RemeGen Co's 12-1 Month Momentum % is 39.44%.
The industry rank for RemeGen Co's 12-1 Month Momentum % or its related term are showing as below:
FRA:REG's 12-1 Month Momentum % is ranked better than 76.23% of 1359
companies
in the Biotechnology industry
Industry Median: -13.88
vs FRA:REG: 39.44
RemeGen Co (FRA:REG) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
RemeGen Co 12-1 Month Momentum % Related Terms
FRA:REG vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, RemeGen Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where RemeGen Co's 12-1 Month Momentum % falls into.
RemeGen Co (FRA:REG) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a 12-1 Month Momentum % of 39.44% as of Aug. 07, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #323 out of 1359 companies in the Biotechnology industry, placing it in the top 23.8%.
Is RemeGen Co's 12-1 Month Momentum % too high?
RemeGen Co's current 12-1 Month Momentum % is 39.44%. Based on the distribution chart, RemeGen Co ranks #323 out of 1359 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #323 out of 1359 companies for 12-1 Month Momentum %. This places RemeGen Co in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on RemeGen Co and its competitors. RemeGen Co's current 12-1 Month Momentum % is 39.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €19.59, compared to a current price of €9.51 — trading 51.4% below its estimated fair value. The current 12-1 Month Momentum % is 39.44%. RemeGen Co's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current 12-1 Month Momentum % is 39.44% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.51 is trading 51.4% below its estimated GF Value™ of €19.59.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
12-1 Month Momentum %: 39.44%
GF Value™: €19.59 vs. price of €9.51 (51.4% below fair value)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
46GF Score
Get the complete analysis for FRA:REG
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
